SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is dominating conversations following reports of record-breaking vehicle deliveries for December and the fourth quarter, fueling strong community speculation about the company achieving its first profitable quarter. The electric vehicle maker's performance, alongside extended government subsidies for new energy vehicles in China, is generating bullish sentiment regarding its growth trajectory and competitive position against rivals. Despite some investor concern about market volatility, many remain focused on NIO's operational advancements.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to its strategic sale of Bressner Technology, which has boosted its cash reserves and sharpened its focus on core AI and edge computing. The community is actively discussing the company's recent stronger-than-expected earnings and raised guidance, alongside high anticipation for a significant military contract for 360 situational awareness systems. Many investors view OSS as an undervalued pure-play in the growing Edge AI and defense sectors, highlighting its tight float and institutional interest.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is drawing significant attention following robust Q3 earnings and strategic moves to bolster its ETF business through acquisitions, alongside its prominent role in a rebounding M&A market. The community is actively discussing the stock's impressive run and strategic AI integration efforts, with many anticipating continued strength, while others debate its high valuation and the potential for a stock split.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending amid intense frustration as the biotech sector's (XBI) extended bullish rally continues to defy expectations, leading to significant pressure on this 3x leveraged bear ETF. The community is sharply divided, with many anticipating an imminent, overdue reversal due to XBI's stretched technicals and high RSI, while others caution against fighting the sector's persistent upward momentum.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following the FDA's acceptance of its sNDA for AXS-05 in Alzheimer's disease agitation with Priority Review, setting a PDUFA target in April 2026. This significant regulatory clarity, coupled with positive updates for AXS-12 in narcolepsy and continued strong Auvelity script growth, is fueling widespread optimism among investors. The community is celebrating substantial long-term gains and actively discussing AXSM's potential to become a major CNS powerhouse, anticipating further analyst upgrades and robust performance as the company advances its diverse pipeline and commercial footprint.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed interim Phase 2 results for its ARCT-032 cystic fibrosis therapy, which showed signs of mucus plug reduction but limited lung function improvement, leading to significant stock volatility. Community sentiment is divided, with many viewing the sharp decline as an overreaction and highlighting the therapy's biological activity, the strength of their mRNA platform, other pipeline assets, and a high-stakes trade secret lawsuit against AbbVie as key discussion points for future value. Simultaneously, discussions around their influenza vaccine candidates are gaining traction amidst concerns over emerging flu variants.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending as its directors and officers extended their share lock-up until September 2026, signaling strong insider confidence and aligning with promising preliminary Phase 3 trial data showing a significant reduction in breast cancer recurrence. The community is actively discussing a potential short squeeze, fueled by an extremely high cost-to-borrow and limited shares available, while long-term investors anticipate a strategic transaction or significant valuation re-rating for this low-float biotech.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals is trending due to the accumulating global regulatory approvals for EKTERLY, its innovative oral on-demand hereditary angioedema treatment, with Japan being the latest market. The community is actively discussing the drug's strong initial sales performance and its significant market advantage as the first oral option, fueling optimism for its global commercialization. Analysts are reinforcing bullish sentiment, recognizing the company's trajectory towards profitability and its strategic position within the biotech sector, with many anticipating further upside.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is currently trending following key regulatory approvals for its Renergen acquisition and new "Overweight" analyst coverage with a bullish price target. Despite these positive developments, community discussion reflects significant frustration over perceived management missteps, repeated commercial shipment delays, and ongoing dilution concerns. This creates a polarized sentiment, balancing long-term potential in critical isotope markets against short-term execution challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company projects FY26 adjusted EPS in the range of €1.90 to €2.05.</li><li>It estimates FY26 revenue in the range of €2.30 billion to €2.35 billion.</li><li>Birkenstock cited headwinds from currency translation and incremental tariffs on its projections.</li></ul>Birkenstock Holding (<a href="https://stocktwits.com/symbol/BIRK">BIRK</a>) shares tumbled nearly 12% in Thursday’s premarket after the company’s FY26 revenue and adjusted profit projections fell below analyst estimates, as tariff uncertainty weighs on demand. &nbsp;&nbsp;The company that largely makes its products in Germany has increased prices to mitigate the impact of Donald Trump’s 15% tariffs on EU imports, but continues to see muted sales growth as it joins a slew of consumer companies hurt by sweeping U.S. tariffs and elevated inflation.&nbsp;The German footwear company projected adjusted profit for FY26 in the range of €1.90 to €2.05 per share ($2.23 to $2.40), below analyst estimates of €2.09 per share, according to Fiscal.ai. It also projected a 100-basis-point hit to its annual gross margin due to the tariffs' impact.&nbsp;<h2 class="st-heading-2">Revenue Projections</h2>The company’s FY26 revenue estimate of €2.30 billion to €2.35 billion also fell below the €2.39 billion estimate. However, the company’s fourth quarter (Q4) revenue of €526 million edged above analyst estimates of €521 million, as tariff impact was somewhat cushioned by robust demand for its products.&nbsp;The company said it expects to invest in capital expenditures of €110 million to €130 million in 2026, well above the €85 million it invested in 2025 to expand production capacity.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around BIRK remained ‘extremely bullish’, and message volume remained ‘extremely high’. The stock was among the top 10 trending stocks on Stocktwits.<figure class="image"><img style="aspect-ratio:643/72;" src="https://news.stocktwits-cdn.com/Capture_1_PNG_a8c4c99ec1.webp" alt="On Stocktwits, the retail sentiment around BIRK remained ‘extremely bullish’, and message volume remained ‘extremely high’. " width="643" height="72"></figure>Shares in Birkenstock have fallen 19% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: €1 = $1.17) &nbsp;

Various Birkenstock shoes are displayed on shelves in a Birkenstock store on Ehrenstraße. Photo: Rolf Vennenbernd/dpa (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Birkenstock Stock Tumbles 12% Pre-Market After FY26 Projections Fail To Impress Investors

Birkenstock projected a muted sales growth for FY26, and its adjusted profit estimate came below analyst expectations, as U.S. tariffs continue to impact its business.  

Equity

Birkenstock projected a muted sales growth for FY26, and its adjusted profit estimate came below analyst expectations, as U.S. tariffs continue to impact its business.  


AMC Entertainment Holdings (AMC) is set to unveil its Q2 earnings after market close on Friday. Neither Wall Street nor the stock’s retail investor base seems optimistic about the results.The company has endured a challenging year, impacted by the 2023 actors' and writers' strikes, which significantly curtailed movie releases.Consequently, AMC projected a year-over-year revenue decline of 23.50% for Q2. However, the company also hinted at improved profitability, forecasting a narrower-than-expected loss per share.On Stocktwits, retail sentiment for the stock has improved since it released preliminary numbers, but it remains bearish (44/100) hours before earnings results are due.<figure class="image"><a href="https://stocktwits.com/symbol/AMC"><img style="aspect-ratio:1324/1018;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AMC_sentiment_graph_showing_improvement_from_Jul_22_to_Aug_2_0b99fb2c84.png" alt="AMC sentiment graph showing improvement from Jul 22 to Aug 2.png" width="1324" height="1018"></a><figcaption>AMC sentiment graph showing improvement from Jul 22 to Aug 2</figcaption></figure>The recent smashing success of films like "Deadpool &amp; Wolverine" has boosted attendance, and the company's recent debt restructuring deal has injected a degree of optimism.However, AMC, a known “meme stock” that has experienced a great deal of volatility this year alongside GameStop, has lost nearly 19% of its valuation in 2024.The decision to release Q2 earnings after market close on a Friday adds an element of uncertainty, and could amplify market reactions due to speculation over the weekend. Retail investors may already be hinting at signs of things to come.

AMC Entertainment expects a 23.50% year-over-year fall in its revenue at $1.03 billion

AMC’s Retail Sentiment Bearish As Q2 Report Nears: Movie Magic Fading?

On Stocktwits, retail sentiment for the stock has improved since it released preliminary numbers, but remains bearish hours before earnings results are due.

AMC Entertainment Holdings on Wednesday announced preliminary earnings for the second quarter of 2024. The company expects a 23.50% year-over-year (YoY) fall in its revenue at $1.03 billion. As for its earnings, it expected a net loss of $32.80 million (down from $8.60 million in net income a year ago). Shares of the firm fell nearly 8% following the announcement while retail sentiment continued to trend in extremely bearish territory (18/100) supported by high message volumes.<figure class="image"><img style="aspect-ratio:788/224;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_1_32_10_PM_652954d4bf.png" alt="Retail sentiment trends in extremely bearish territory for AMC Entertainment" width="788" height="224"><figcaption>Retail sentiment trends in extremely bearish territory for AMC Entertainment</figcaption></figure>AMC has attributed the weakness to the prolonged actors’ and writers' strikes of 2023 which severely reduced the number of movies being released theatrically in the early months of 2024.Still, Chairman and CEO Adam Aaron said the firm remains confident that industry-wide movie revenues for the second half of 2024, and into 2025 and 2026 will continue to show increasing strength. “This in turn suggests that AMC should enjoy increasing adjusted earnings before interest, tax, depreciation, and amortization (EBITDA), if and when overall industry revenues are climbing,” he said.The firm is scheduled to report its full results for the second quarter after the market closes on August 2. Retail investors will be awaiting an update on whether the company plans to issue new equity capital to service its large debt loan, which it recently restructured by using its theaters as collateral.The stock hasn’t had a good year so far, having lost over 23% and remaining volatile as part of a core group of “meme stocks” tied to the influence of Roaring Kitty and others. On Wall Street, Macquarie recently raised its price target on the stock from $3.50 to $4.00 while giving an “Underperform” rating suggesting an improving, but still concerning picture.While a trading halt near the market-open allowed Stocktwits users to digest the news, many expressed concern about downside volatility ahead. Meanwhile, one user with a bearish stance on the stock is expecting it to eventually fall back below the $3 mark towards its all-time lows set in April.<figure class="image"><a href="https://stocktwits.com/_RickWithASilentP/message/580572369"><img style="aspect-ratio:789/146;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_1_33_12_PM_66083540ef.png" alt="Stocktwits user _RickWithASilentP's post on AMC Entertainment" width="789" height="146"></a><figcaption>Stocktwits user _RickWithASilentP's post on AMC Entertainment</figcaption></figure>

Retail Investors Hammer AMC Entertainment After It Discloses Preliminary Q2 Earnings: Here’s What The Firm Said

The company expects a 23.50% year-over-year (YoY) fall in its revenue at $1.03 billion while net loss is expected to be approximately $320.80 million, compared to net earnings of $8.60 million for the same period last year. 

The company expects a 23.50% year-over-year (YoY) fall in its revenue at $1.03 billion while net loss is expected to be approximately $320.80 million, compared to net earnings of $8.60 million for the same period last year. Retail remains concerned about further dilution given the company’s continued lack of profitability.

Current Price	$36.04
Prev Close	$36.37
Open	$36.22
Dividend Yield	N/A
50-Day Moving Average	$35.58
Beta	N/A
Avg. Volume	2,341.58
PE Ratio	N/A

52-Week High	$37.42
52-Week Low	$23.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

OPTZ
Advisor Managed Portfolios - Optimize Strategy Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest OPTZ News

OPTZAdvisor Managed Portfolios - Optimize Strategy Index ETF